CleanPlex® Comprehensive Epilepsy Panel

The CleanPlex® Comprehensive Epilepsy Panel is a pre-designed and made-to-order multiplex PCR / amplicon-based targeted sequencing assay for examining the germline variants or mutations across 296 genes associated with Comprehensive Epilepsy.

Clear

Product Description

The CleanPlex® Comprehensive Epilepsy Panel is a pre-designed and made-to-order multiplex PCR / amplicon-based targeted sequencing (NGS) assay designed to examine the germline variants or mutations across 296 genes associated with Comprehensive Epilepsy. The panel targets all the exonic regions of those genes and the flanking intronic sequences. Compatible with just 10 ng of DNA, sequencing-ready libraries can be prepared using a streamlined workflow in just 3 hours. The pre-designed panel is optimized in silico to deliver data with high on-target performance and high coverage uniformity to ensure efficient use of sequencing reads.

This product is made to order. Once we receive your order, we will synthesize the panel and the kit will contain CleanPlex Multiplex PCR Primers and CleanPlex Targeted Library Kit. CleanPlex Indexed PCR Primers and CleanMag® Magnetic Beads can be ordered separately to complete the workflow from input DNA to sequencing-ready NGS libraries.

Storage Temperature

Store at -20 °C.

For Research Use Only. Not for use in diagnostic procedures.

Gene List:
ABAT, ABCD1, ACTL6B, ACY1, ADAM22, ADAR, ADGRG1, ADGRV1, ADSL, AGA, AIFM1, ALDH5A1, ALDH7A1, ALG13, AMACR, AMT, ANKRD11, AP3B2, ARFGEF2, ARG1, ARHGEF9, ARID1B, ARSA, ARX, ASAH1, ASNS, ASPA, ATP13A2, ATP1A2, ATP1A3, ATP6AP2, ATRX, BCKDK, BRAT1, BTD, C12orf57, CACNA1A, CACNA1B, CACNA1D, CACNA1H, CACNA2D2, CACNB4, CARS2, CASK, CASR, CDKL5, CERS1, CHD2, CHRNA2, CHRNA4, CHRNB2, CLCN2, CLCN4, CLN3, CLN5, CLN6, CLN8, CLTC, CNPY3, CNTN2, CNTNAP2, COL18A1, COL4A1, COX15, CPA6, CPT2, CRH, CSTB, CTNNB1, CTSD, CTSF, CUL4B, CYFIP2, DCX, DDX3X, DENND5A, DEPDC5, DHCR7, DHFR, DNAJC5, DNM1, DOCK7, DPYD, DYRK1A, EEF1A2, EFHC1, EHMT1, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, EPM2A, ETFDH, FARS2, FGF12, FH, FKTN, FLNA, FOLR1, FOXG1, FRRS1L, GABBR2, GABRA1, GABRB2, GABRB3, GABRG2, GALC, GAMT, GATM, GCDH, GFAP, GLB1, GLDC, GLRA1, GLRB, GNAO1, GNB1, GNE, GOSR2, GPAA1, GPHN, GRIA3, GRIN1, GRIN2A, GRIN2B, GRN, HCN1, HCN2, HECW2, HNRNPU, HSD17B10, IER3IP1, IQSEC2, IRF2BPL, ITPA, KANSL1, KCNA1, KCNA2, KCNB1, KCNC1, KCNH1, KCNH2, KCNJ10, KCNMA1, KCNQ2, KCNQ3, KCNT1, KCTD7, KDM5C, KDM6A, KIAA2022, L2HGDH, LGI1, LIAS, LRPPRC, MAGI2, MBD5, MDH2, MECP2, MED12, MED17, MEF2C, MFSD8, MLC1, MOCS1, MTFMT, MTHFR, MTOR, NACC1, NDST1, NDUFS4, NDUFS7, NDUFS8, NDUFV1, NECAP1, NEDD4L, NEU1, NEXMIF, NF1, NGLY1, NHLRC1, NOTCH3, NPRL3, NR2F1, NRXN1, NSD1, NUS1, OFD1, OPHN1, PACS1, PAFAH1B1, PAK3, PCDH19, PGK1, PHF6, PIGA, PIGG, PIGN, PIGO, PIGP, PIGT, PIGV, PIGW, PLAA, PLCB1, PLP1, PLPBP, PNKP, PNPO, POLG, POMT1, POMT2, PPP3CA, PPT1, PQBP1, PRICKLE1, PRIMA1, PRODH, PRRT2, PSAP, PURA, QARS, QDPR, RAB39B, RELN, RNASEH2A, RNASEH2B, RNASEH2C, ROGDI, RORB, SAMHD1, SATB2, SCARB2, SCN10A, SCN1A, SCN1B, SCN2A, SCN3A, SCN8A, SCN9A, SERPINI1, SETBP1, SIK1, SLC12A5, SLC13A5, SLC17A5, SLC19A3, SLC25A12, SLC25A15, SLC25A22, SLC2A1, SLC35A2, SLC46A1, SLC6A1, SLC6A8, SLC9A6, SMARCA2, SMC1A, SMS, SNAP25, SPATA5, SPTAN1, ST3GAL3, ST3GAL5, STRADA, STX1B, STXBP1, SUMF1, SUOX, SYN1, SYNGAP1, SYNJ1, SZT2, TBC1D24, TBL1XR1, TCF4, TNK2, TPK1, TPP1, TREX1, TSC1, TSC2, TUBA1A, TUBA8, TUBB2A, TUBB2B, UBA5, UBE2A, UBE3A, UNC80, VPS13A, WASF1, WDR45, WWOX, ZEB2

References:
Baldassari S, et al. GATOR1 complex: the common genetic actor in focal epilepsies. J Med Genet. 2016 Aug;53(8):503-10.

Boerma RS, et al. Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach. Neurotherapeutics. 2016 Jan;13(1):192-7.

Hildebrand MS, et al. A targeted resequencing gene panel for focal epilepsy. Neurology. 2016 Apr 26;86(17):1605-12.

Mikati MA, et al. Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol. 2015 Dec;78(6):995-9.

Palavra F, et al. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. Oxid Med Cell Longev. 2017;2017:9820181.

Scheffer IE, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):512-521.

Additional Information

Weight40 g
Dimensions10 x 7 x 5 cm
Pack Size (Reactions)

1000

For early access to our upcoming Respiratory Research Panel combining Influenza A/B and SARS-CoV-2 testing, please visit HERE. Dismiss